Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.78 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.78 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.78 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.78 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9550969 | 1.00 | SLC28A1 (0.78) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL18464386 | 1.00 | SLC28A1 (0.78) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL18464135 | 1.00 | SLC28A1 (0.78) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL11980429 | 1.00 | SLC28A1 (0.78) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL13828184 | 1.00 | SLC28A1 (0.78) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL18180942 | 1.00 | SLC28A1 (0.78) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL17199513 | 1.00 | SLC28A1 (0.78) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL881866 | 1.00 | SLC28A1 (0.78) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL14232548 | 1.00 | SLC28A1 (0.78) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1527257 | 1.00 | SLC28A1 (0.78) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12343420-B2 | Stabilized polyribonucleotide coding for an elastic fibrous protein | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2025-07-01 | — | — | US | claimed |
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| EP-4306643-A2 | PLASMID CONTAINING A SEQUENCE ENCODING AN MRNA WITH A SEGMENTED POLY(A) TAIL | ethris GmbH (DE) | 2024-01-17 | — | — | EP | claimed |
| US-20220249346-A1 | STABILIZED POLYRIBONUCLEOTIDE CODING FOR AN ELASTIC FIBROUS PROTEIN | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2022-08-11 | — | — | US | claimed |
| EP-3165234-A1 | RNA WITH A COMBINATION OF UNMODIFIED AND MODIFIED NUCLEOTIDES FOR PROTEIN EXPRESSION | ethris GmbH (DE) | 2017-05-10 | — | — | EP | claimed |
| CN-113396219-B | Purification of mRNA by tangential flow filtration | ETHRIS GMBH (DE) | 2026-05-26 | — | — | CN | disclosed |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4705284-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-3752610-B1 | POLYRIBONUCLEOTIDE CONTAINING DEUTERATED NUCLEOTIDES | ETHRIS GMBH (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-12522821-B2 | Polyribonucleotide containing deuterated nucleotides | ETHRIS GMBH (DE) | 2026-01-13 | — | — | US | disclosed |
| US-12509679-B2 | mRNA purification by tangential flow filtration | ETHRIS GMBH (DE) | 2025-12-30 | — | — | US | disclosed |
| US-6307040-B1 | MIXED SEQUENCE OLIGONUCLEOTIDE HAVING AT LEAST ONE MODIFIED 2'-DEOXYFURANOSYL MOIETY MODIFIED BY SUBSTITUTION WITH HALO, AZIDO, AMINO, SUBSTITUTED AMINO, HALOMETHYL, CYANATO, HALOALKOXYL, ALKYL SULFIDE OR SULFONATE, NITRATE OR NITRITE | ISIS PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6005087-A | NUCLEASE RESISTANT OLIGONUCLEOTIDES WHICH ARE USEFUL AS THERAPEUTICS, DIAGNOSTICS, AND RESEARCH REAGENTS FOR VARIOUS VIRAL DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| US-5872232-A | 2'-O-modified oligonucleotides | ISIS PHARMACEUTICALS INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5859221-A | HYBRID DNA, RNA; NUCLEASE RESISTANT | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5670633-A | TREATMENT AND DIAGNOSIS OF DISEASES AMENABLE TO MODULATION OF THE PRODUCTION OF SELECTED PROTEINS | ISIS PHARMACEUTICALS, INC. (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0549615-A4 | SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 1997-08-27 | — | — | EP | disclosed |
| EP-0549615-A1 | SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| WO-1992003568-A1 | SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | SARS1, ITK, SLC43A1 | SLC28A1 19/4885SLC28A2 30/4885SLC29A1 16/4885 |
| US-12509679-B2 | mRNA purification by tangential flow filtration | ELL, RNGTT, FIP1L1 | SLC28A1 1016/4885SLC28A2 816/4885SLC29A1 1244/4885 |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NSUN2, SARS1, SNRPE | SLC28A1 19/4885SLC28A2 35/4885SLC29A1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.